Abstract

Drospirenone is a synthetic progestogen contained, with estradiol, in the hormone replacement therapy (HRT) product ▼Angeliq (Bayer Schering Pharma). This combination is licensed for the relief of oestrogen-deficiency symptoms in women who are at least 1 year postmenopausal.1 It is also licensed for prevention of osteoporosis in women at high risk of future fractures who are intolerant of, or have contraindications to, other medicinal products approved for the prevention of osteoporosis.1 It has also been suggested that drospirenone may have an antihypertensive effect.2 Here we discuss the place of this drug for women following a natural menopause.